Emergent BioSolutions (EBS) Tops Q2 EPS by 26c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.73 +3.96%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.9 million versus the consensus estimate of $174 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robinhood Ventures Fund II opens at $22.50, IPO at $25
- Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
- Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
